| Revision as of 05:24, 17 December 2009 editSmackBot (talk | contribs)3,734,324 editsm remove Erik9bot category,outdated, tag and general fixes← Previous edit | Revision as of 18:05, 29 July 2010 edit undoPotatoBot (talk | contribs)Bots51,239 editsm Stub sorting and placement of stub template(s)Next edit → | ||
| Line 35: | Line 35: | ||
| {{ |
{{respiratory-system-drug-stub}} | ||
| ] | ] | ||
Revision as of 18:05, 29 July 2010
 | This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Tyloxapol" – news · newspapers · books · scholar · JSTOR (December 2009) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.209.660  |
| Chemical and physical data | |
| Formula | (C15H21O(C2H4O)m)n |
| Molar mass | variable |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.
 | This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it. |